Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review
Hanan Muzeyin Kedir,Eskinder Ayalew Sisay,Alfoalem Araba Abiye
DOI: https://doi.org/10.2147/IJGM.S326929
IF: 2.145
2021-08-24
International Journal of General Medicine
Abstract:Hanan Muzeyin Kedir, Eskinder Ayalew Sisay, Alfoalem Araba Abiye Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Correspondence: Hanan Muzeyin Kedir Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health Sciences, Addis Ababa University, P.O.Box: 1176, Addis Ababa, Ethiopia Tel +251912275828 Email Introduction: Aspirin appeared as a medicine to deal with aches and inflammation, but due to its antiplatelet properties, it has evolved into a drug mainly used to avert cardiovascular disease. Regardless of its therapeutic uses, the limiting aspect for aspirin use has been its affiliation with gastrointestinal (GI) toxicity, classifying from acute mucosal damage to GI problems and death. Objective: The aim of this systematic review is to address the question regarding the ECA effect on the gastric mucosa. Methods: A systematic search of the literature was conducted in the PubMed electronic databases from April 10th to April 23rd, 2020. Eligibility has been set, and based on those criteria, initially a total of 637 results were obtained, from these 58 of them were not written in English. Then, 168 articles which were free from duplication were screened and all the included articles were RCTs published after 2000. Based on these, final number of articles included on this review was 6. Results: Data were obtained from 6 published articles which reported on 15,621 participants. The reports were from 3 different countries. Most of the studies revealed that enteric-coated aspirin (ECA) treatment was not an effective mechanism against GI protection. ECA administration with omeprazole can hugely reduce the incidence of endoscopic GI damage compared to the impact of ECA used alone. Even short-term administration of a low dose of ECA was significantly associated with an apparent small bowel injury. Conclusion: ECA treatment is not an effective mechanism against GI protection, and it is highly associated with small bowel injury. So the coating does not reduce risk of GI complications. Keywords: enteric coated, aspirin, gastrointestinal, side effects Initially aspirin was as a medicine to deal with aches and inflammation, but due to its antiplatelet properties, it has evolved into a drug mainly used to avert cardiovascular disease. 1 Long-term use of low-dose aspirin, often described as 75–325 mg daily, is for primary and secondary prevention of cardiovascular disease such as myocardial infarction. 2–5 Regardless of its therapeutic uses, the limiting aspect for aspirin use has been its affiliation with gastrointestinal (GI) toxicity, classifying from acute mucosal damage to GI problems and death. 6–8 Aspirin is a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase, an important enzyme in the biosynthesis of prostaglandins 1. The mechanisms by which aspirin causes GI mucosal damage are thought to be by both direct topical injury on the epithelium and mainly, a systemic effect associated to prostaglandin depletion. 9,10 Different research has mentioned the risk factors for aspirin-induced GI complications, such as higher aspirin dose, advanced age, history of peptic ulcer disease, use of combinations of non-steroidal anti-inflammatory drugs and concomitant use of drugs such as steroids or anticoagulants. 11,12 There are mechanisms used to diminish aspirin-associated GI injury, like reducing the dose of aspirin 6,13 and use of aspirin with a gastro-protective agents like proton pump inhibitors. 11 Adjustments also have been made in attempts to make aspirin greater tolerable in the GI tract, 14 such as designing enteric-coated aspirin (ECA) with cellulose or silicon which resists disintegration in the stomach, permitting aspirin to dissolve specifically in the duodenum, the place the pH is more alkaline, or using buffering agents, such as calcium carbonate, magnesium oxide, or magnesium carbonate, which lower the hydrogen ion concentration in the GI tract. 1 Previously published systematic reviews indicated that there is a reduction of gastric mucosal injury with ECA formulation. 15 Whereas, recent studies demonstrate that using of enteric-coated formulations of aspirin may also no longer influence the incidence rate of clinically relevant GI outcomes. 14 In terms of frequency or severity of damage, ECA no longer provided any advantage over plain aspirin and did not minimize the chance of peptic ulcer formation and GI bleeding, 16,17 because the effect of both plain and ECA on upper GI bleeding is particularly systemic. 18 Hence, the aim of t -Abstract Truncated-
medicine, general & internal